- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances in the Treatment of Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-06-14
DOI
10.3389/fonc.2018.00227
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Study of Taselisib (GDC‑0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
- (2018) Maura N. Dickler et al. CLINICAL CANCER RESEARCH
- PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
- (2017) Mathilde Guerin et al. EUROPEAN JOURNAL OF CANCER
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent advances of highly selective CDK4/6 inhibitors in breast cancer
- (2017) Hanxiao Xu et al. Journal of Hematology & Oncology
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
- (2017) April A.N. Rose et al. PHARMACOLOGY & THERAPEUTICS
- A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
- (2016) Steven A. Limentani et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
- (2016) Amy Jo Chien et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
- (2016) Giuseppe Curigliano et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
- (2016) Romualdo Barroso-Sousa et al. Breast Care
- PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
- (2016) G E Konecny et al. BRITISH JOURNAL OF CANCER
- PARP inhibitors: the race is on
- (2016) Jessica S Brown et al. BRITISH JOURNAL OF CANCER
- Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer
- (2016) Hirofumi Mukai et al. CANCER SCIENCE
- Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order
- (2016) Edith A. Perez DRUG RESISTANCE UPDATES
- Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer
- (2016) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
- (2015) Carlos Acevedo-Gadea et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
- (2015) Kimberly Blackwell et al. BREAST CANCER RESEARCH AND TREATMENT
- Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer
- (2015) Milton Seiler et al. Clinical Breast Cancer
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- Triple-negative breast cancer: new perspectives for targeted therapies
- (2015) Silverio Tomao et al. OncoTargets and Therapy
- Optimal management of hormone receptor positive metastatic breast cancer in 2016
- (2015) Tomas Reinert et al. Therapeutic Advances in Medical Oncology
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
- (2014) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
- (2014) Sara Tolaney et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
- (2014) C. Saura et al. CLINICAL CANCER RESEARCH
- Past, Present, and Future Challenges in Breast Cancer Treatment
- (2014) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
- (2014) Dimitrios H. Roukos et al. OncoTargets and Therapy
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells
- (2013) Elizabeth M.H. Kim et al. JOURNAL OF SURGICAL RESEARCH
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- Antibodies to watch in 2013
- (2013) Janice M Reichert mAbs
- The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
- (2013) Véronique Diéras et al. Targeted Oncology
- Phase II trial of temsirolimus in patients with metastatic breast cancer
- (2012) Gini F. Fleming et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
- (2012) Bojana Milojkovic Kerklaan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades
- (2012) R. Haque et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
- (2012) Erika Hamilton et al. Journal of Translational Medicine
- Abstract B161: U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates preclinical efficacy in HER2+ and HER2- breast cancer models
- (2012) T. Hettman et al. MOLECULAR CANCER THERAPEUTICS
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Functional Activation of the Estrogen Receptor- and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
- (2011) G. J. Sabnis et al. CANCER RESEARCH
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
- (2011) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Heterogeneity in breast cancer
- (2011) Kornelia Polyak JOURNAL OF CLINICAL INVESTIGATION
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of Breast Cancer in the United States: Current and Future Trends
- (2011) W. F. Anderson et al. JNCI-Journal of the National Cancer Institute
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Steroid sulfatase: A pivotal player in estrogen synthesis and metabolism
- (2011) Atul Purohit et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
- (2010) N. Berrada et al. ANNALS OF ONCOLOGY
- Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
- (2010) A. A. N. Rose et al. CLINICAL CANCER RESEARCH
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients
- (2010) H. G. Russnes et al. Science Translational Medicine
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now